Exelixis, Inc. (LON:0IJO)
37.77
+1.09 (2.98%)
At close: Aug 1, 2025
Exelixis Revenue
Exelixis had revenue of $568.26M USD in the quarter ending June 30, 2025, a decrease of -10.82%. This brings the company's revenue in the last twelve months to $2.23B, up 10.73% year-over-year. In the year 2024, Exelixis had annual revenue of $2.17B with 18.49% growth.
Revenue (ttm)
$2.23B
Revenue Growth
+10.73%
P/S Ratio
4.65
Revenue / Employee
$1.94M
Employees
1,147
Market Cap
7.57B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.17B | 338.49M | 18.49% |
Dec 31, 2023 | 1.83B | 219.15M | 13.60% |
Dec 31, 2022 | 1.61B | 176.09M | 12.27% |
Dec 31, 2021 | 1.43B | 447.43M | 45.31% |
Dec 31, 2020 | 987.54M | 19.76M | 2.04% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |
Exelixis News
- 4 days ago - Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans - Benzinga
- 4 days ago - Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans - Benzinga
- 4 days ago - These Stocks Are Moving the Most Today: UnitedHealth, Sarepta, UPS, Whirlpool, VeriSign, Cadence Design, Exelixis, and More - Barron's
- 4 days ago - Exelixis Inc (EXEL) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Challenges - GuruFocus
- 4 days ago - Exelixis outlines continued cabozantinib growth and zanzalintinib pipeline acceleration as new launches drive 19% revenue increase - Seeking Alpha
- 4 days ago - Exelixis, Inc. (EXEL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Exelixis slides 12% on Q2 misses, pipeline update - Seeking Alpha
- 4 days ago - Exelixis Q2 Revenue Falls 11 Percent - The Motley Fool